Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
about
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin.Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
P2860
Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Real-world medication persiste ...... ith type 2 diabetes in the US.
@en
Real-world medication persiste ...... ith type 2 diabetes in the US.
@nl
type
label
Real-world medication persiste ...... ith type 2 diabetes in the US.
@en
Real-world medication persiste ...... ith type 2 diabetes in the US.
@nl
prefLabel
Real-world medication persiste ...... ith type 2 diabetes in the US.
@en
Real-world medication persiste ...... ith type 2 diabetes in the US.
@nl
P2860
P356
P1476
Real-world medication persiste ...... ith type 2 diabetes in the US.
@en
P2860
P356
10.2147/CEOR.S117200
P407
P577
2016-12-22T00:00:00Z